Harness the power of highly potent, tumor-selective immuno-oncology (I-O) therapies to provide effective, tolerable and durable therapeutic options for patients and their physicians.
We are using our proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effect, resulting in the potential to achieve enhanced anti-tumor activity. We are building a pipeline of wholly-owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates. Please click on the links below to learn more:
What tumor-selective immunotherapy could mean for cancer patients
Chrissy was a chef and mother of two, who was diagnosed with lung cancer and passed away in July 2021 after a long and courageous battle. She was committed to treating the disease aggressively, but her therapies caused severe side effects, including severe dehydration, swelling, vascular leak syndrome, fatigue, dizziness, mouth sores, back pain, and heartburn. Minimizing toxicity with a tumor-selective approach could allow for more effective anti-tumor treatment without debilitating adverse events for patients like Chrissy in the future.